Egetis Therapeutics AB (publ)

LSE:0ABW Stock Report

Market Cap: SEK 2.3b

Egetis Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

LSE:0ABW Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
08 Nov 24BuySEK 25,020Christian SonessonIndividual6,000SEK 4.22
08 Nov 24BuySEK 280,150Henrik KrookIndividual65,000SEK 4.31
07 Oct 24BuySEK 42,250Yilmaz MahshidIndividual10,000SEK 4.23
07 Oct 24BuySEK 43,103Nicklas WesterholmIndividual10,142SEK 4.25

Insider Trading Volume

Insider Buying: 0ABW insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 0ABW?
Owner TypeNumber of SharesOwnership Percentage
VC/PE Firms38,675,50110.8%
Individual Insiders48,059,32813.4%
Private Companies61,976,21117.3%
Institutions65,711,67518.3%
General Public144,815,41140.3%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.8%.


Top Shareholders

Top 25 shareholders own 59.65% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.8%
Frazier Life Sciences Management, LP
38,675,501SEK 243.7m0%0.89%
9.4%
Cetoros AB
33,776,221SEK 212.8m0%no data
8.35%
Peter Lindell
30,007,682SEK 189.0m0%no data
5.96%
Fourth Swedish National Pension Fund (AP4)
21,404,690SEK 134.8m0%0.05%
4.92%
Avla Holding AB
17,668,330SEK 111.3m0%no data
3.85%
Flerie AB (publ)
13,844,458SEK 87.2m0%13.56%
3.76%
Thomas Eldered
13,499,458SEK 85.0m0%no data
3.29%
Handelsbanken Asset Management
11,831,897SEK 74.5m0%0.01%
2.93%
Recipharm AB (publ)
10,531,660SEK 66.3m0%no data
2.1%
Linc AB
7,532,021SEK 47.5m0%1.99%
1.93%
Unionen, Endowment Arm
6,946,793SEK 43.8m0%1.25%
0.87%
Mats Blom
3,134,762SEK 19.7m0%no data
0.43%
SEB Investment Management AB
1,538,387SEK 9.7m1.21%no data
0.28%
Swedbank Robur Fonder AB
1,000,000SEK 6.3m0%no data
0.21%
FCG Fonder AB
772,249SEK 4.9m0%0.05%
0.11%
Henrik Krook
404,593SEK 2.5m19.1%no data
0.087%
Yilmaz Mahshid
313,089SEK 2.0m3.3%no data
0.086%
Financiere Arbevel
310,000SEK 2.0m0%0.04%
0.079%
Thomas Lonngren
283,158SEK 1.8m0%no data
0.07%
Avanza Fonder AB
250,662SEK 1.6m0%no data
0.068%
Nicklas Westerholm
242,718SEK 1.5m4.36%no data
0.049%
Skandia Fonder AB
176,659SEK 1.1m0%no data
0.021%
Storebrand Fonder AB,
73,895SEK 465.5k0%no data
0.012%
Christian Sonesson
42,298SEK 266.4k16.5%no data
0.011%
Gunilla Osswald
40,000SEK 251.9k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 10:13
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Egetis Therapeutics AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Patrick LangstromABG Sundal Collier Sponsored
Oscar Haffen LammBryan Garnier & Co